An interventional study of Endoscopic surgery in Intracerebral Hemorrhage, sponsored by MicroPort NeuroTech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by MicroPort NeuroTech Co., Ltd. (formerly part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment
Among 122 studies in Cerebral Hemorrhage with a site in China — 58 open to participants now, 61 under way, 5 of them phase 3. Cerebral Hemorrhage · China.
Among the 122 studies in Cerebral Hemorrhage with a site in China, this one is the 73rd largest by planned enrollment of the 77 interventional ones that give a count, is one of 20 that started in 2025, is one of 35 with no phase, reaches primary completion later than 12 of the 60 other live ones, and was the 90th registered.
457 studies on the registry are indexed under Cerebral Hemorrhage; 172 are open to participants now.
Browse Cerebral Hemorrhage studies →58 of the 122 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 12–70
Jiangsu Province (Suqian) Hospital · Sites in China
Ages 65+
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Yanyan Gong · Sites in China
Ages 18–85
Beijing Tiantan Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 112 Cerebral Hemorrhage studies recruiting now, 58 (52%) set no upper age limit and 9 (8%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 20 · Phase 3 14 · Phase 4 4
First in 2005; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 100 across 269 interventional studies indexed under Cerebral Hemorrhage.
Median enrollment 180 across the 77 interventional studies, 698 across the 45 observational. Of the 31 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 122 have an industry lead sponsor. The 10 most frequent:
This study is registered under MicroPort NeuroTech Co., Ltd., one of the names counted as MicroPort Scientific Corporation. Under that name alone:
MicroPort NeuroTech Co., Ltd. is the lead sponsor of 13 studies on the registry; 7 are open to participants now.
MicroPort Scientific Corporation has 1 study filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
14 of the studies in Cerebral Hemorrhage with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06868511Phase 3Beijing Tiantan HospitalNeuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage | 2027-03-01 |
| NCT06688162Capital Medical UniversityMinimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage--Small Hemorrhage Evacuation (MIRACLE-S) | 2026-11-30 |
| NCT06688201Capital Medical UniversityMinimally Invasive Soft Channel Brain Haemorrhage Evacuation for Acute Basal Ganglia Haemorrhage-- Large Hemorrhage Evacuation (MIRACLE-L) | 2026-11-30 |
| NCT03571763General Hospital of Shenyang Military RegionThe Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients | 2026-12-30 |
| NCT07311343Beijing Tiantan HospitalOral Hygiene and Prophylactic Antibiotics to Prevent Intracerebral Hemorrhage Associated Pneumonia | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 122 studies in Cerebral Hemorrhage with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial is a prospective, open-label, single-arm clinical trial. According to the inclusion and exclusion criteria specified in the trial protocol, no fewer than 16 subjects with cerebral hemorrhage will be enrolled in 1 to 2 clinical centers. Considering the learning period required for doctor to become proficient in using the device, the first three cases at each research center are considered as the lead-in period cases and will not be included in the primary analysis dataset. During the surgery, a disposable intracerebral aspiration endoscope will be used to remove the intracerebral hematoma. Follow-ups will be conducted at discharge/Day 7 (±1 day), postoperative 1 month (±7 days), and postoperative 3 months (±15 days). Recording various indicators to evaluate the safety and effectiveness of the disposable intracerebral aspiration endoscope in treating intracerebral hematoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Multiple intracerebral hemorrhages;
Note: Hemorrhage in the supratentorial subcortical or basal ganglia region that extends into the ventricles is not considered multiple hemorrhages and can be included.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Using a disposable intracerebral aspiration endoscope to remove the intracerebral hematoma
Procedure: Endoscopic surgery
Using a disposable intracerebral aspiration endoscope to remove the intracerebral hematoma
Intracerebral hematoma clearance rate
Perform a brain CT scan within 24 hours after surgery, comparing it with the baseline CT, and calculating the proportion of hematoma volume reduction.
Time frame: Day 0（within 24 hours after procedure）
Hospitalization duration
Time frame: During the days at hospital(up to 105 days)
Intensive Care Unit(ICU) duration
Time frame: During the days at Intensive Care Unit(ICU)(up to 105 days)
The proportion of subjects with an mRS score of ≤3 at 3 months after surgery
Time frame: 3 months after surgery(±15days)
The incidence of rebleeding at the surgical site within 7 days after surgery or before discharge.
Time frame: 7 days (±1day) after surgery or before discharge.
The incidence of reoperation due to rebleeding at the surgical site during the follow-up period.
Time frame: 3 months after surgery(±15days)
All-cause mortality
Time frame: 3 months after surgery(±15days)
Device-related SAE
Time frame: 3 months after surgery(±15days)
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Aug 2025, 6 months after the start.
Of 84 interventional studies with no phase under Cerebral Hemorrhage, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 72. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MicroPort NeuroTech Co., Ltd. →